News
06-02-2015, 02:01 AM
Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
More... (http://www.news-medical.net/news/20150602/Enzalutamide-Phase-2-study-for-AR-positive-triple-negative-breast-cancer-meets-primary-endpoint.aspx)
More... (http://www.news-medical.net/news/20150602/Enzalutamide-Phase-2-study-for-AR-positive-triple-negative-breast-cancer-meets-primary-endpoint.aspx)